A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

PHASE3CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

August 10, 2019

Primary Completion Date

August 11, 2021

Study Completion Date

August 5, 2022

Conditions

Palmoplantar Pustulosis

Interventions

DRUG

KHK4827

brodalumab 210mg Q2W, SC

DRUG

Placebo

Q2W, SC

Trial Locations (2)

Takagi Dermatology clinic, Obihiro

Sapporo Dermatology clinic, Sapporo

All Listed Sponsors

lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT04061252 - A Study of KHK4827 in Subjects With Palmoplantar Pustulosis | Biotech Hunter | Biotech Hunter